Guggenheim initiated coverage of Pyxis Oncology (PYXS) with a Buy rating and $5 price target The firm believes the market may incorrectly written off micvotabart pelidotin, a first-in-concept non-internalizing antibody-drug conjugate against the novel target extra-domain B splice variant of fibronectin in the tumor stroma. The analyst thinks Pyxis may have a viable development path for micvotabart.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PYXS:
- Pyxis Oncology initiated with a Buy at Guggenheim
- Optimistic Buy Rating for Pyxis Oncology Driven by Promising MICVO Developments and Strategic Merck Collaboration
- Buy Rating for Pyxis Oncology: Promising Prospects for Micvo and Strong Financial Position
- Pyxis Oncology Reports Q2 2025 Financial Results
- Pyxis Oncology reports Q2 EPS (30c), consensus (35c)